FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海昊海生物科技股份有限公司 (「本公司」)（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06826 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,740 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 36,509,740 | RMB | | 1 RMB | | 36,509,74 ...

证券日报网讯 2月27日，昊海生科发布2025年度业绩快报公告称，公司2025年实现营业总收入247301.23 万元，同比下降8.33%。 （文章来源：证券日报） ...

Core Viewpoint - Haohai Biological Technology (688366) reported a decline in both revenue and net profit for the fiscal year 2025, attributed to increased competition and a decrease in domestic cataract surgery volume [1] Group 1: Financial Performance - The company achieved an operating revenue of approximately 2.473 billion yuan, a year-on-year decrease of 8.33% [1] - The net profit attributable to shareholders was about 251 million yuan, reflecting a year-on-year decline of 40.3% [1] Group 2: Market Conditions - The domestic cataract surgery total in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [1] - Increased competition in the market, particularly from domestic brands offering significant cost advantages, has pressured the sales of imported products [1] Group 3: Impairment Provisions - The company has made a prudent decision to recognize an impairment provision of approximately 140 million yuan for the goodwill of its subsidiary Shenzhen New Industry [1] - Additionally, the U.S. subsidiary Aaren Scientific Inc. has indicated signs of impairment for its intangible assets, leading to a provision of about 24.98 million yuan [2]

Group 1 - The company reported a revenue of 2.473 billion yuan for the fiscal year 2025, representing a year-on-year decrease of 8.33% [1] - The net profit attributable to the parent company was 251 million yuan, down 40.30% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 160 million yuan, a decrease of 57.67% year-on-year [1] Group 2 - The company's subsidiary, Shenzhen New Industry Ophthalmic New Technology Co., faced significant operational pressure due to the second phase of the national volume-based procurement for artificial lenses and intensified industry competition [2] - The total number of cataract surgeries in China in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [2] - The increase in domestic competitors, particularly those offering significant cost advantages, has negatively impacted the sales price and volume of the imported Lenstec brand products [2] - The company anticipates a decrease in sales profit for Shenzhen New Industry in 2025 and has prudently recognized an impairment provision of approximately 140 million yuan for goodwill [2]

Core Viewpoint - The company, Haohai Biological Technology, reported a decline in revenue and net profit for the fiscal year 2025, indicating significant operational challenges in the artificial lens market due to increased competition and changing market dynamics [1][2]. Group 1: Financial Performance - Total revenue for 2025 was approximately 2.473 billion yuan, a year-on-year decrease of 8.33% [1] - Net profit attributable to the parent company was about 251 million yuan, down 40.3% year-on-year [1] - Net profit excluding non-recurring gains and losses was approximately 160 million yuan, reflecting a 57.67% decrease year-on-year [1] - Basic earnings per share stood at 1.08 yuan [1] Group 2: Market Conditions - The domestic cataract surgery volume in 2025 is expected to decline compared to 2024, leading to an overall market demand drop [2] - Increased competition in the market, particularly from domestic lens products that offer significant cost and price advantages over imported brands, is putting pressure on sales [2] - Sales prices and volumes of the Lenstec brand artificial lenses are experiencing a continuous downward trend in 2025 [2] Group 3: Impairment Provisions - The company has made a prudent decision to recognize an impairment provision of approximately 140 million yuan for goodwill related to its subsidiary Shenzhen New Industry due to underperformance [2] - The impairment amount is subject to final assessment and audit by qualified evaluation and auditing institutions [2] - Additionally, the company recognized an impairment provision of about 24.98 million yuan for intangible assets related to its U.S. subsidiary Aaren Scientific Inc. due to signs of impairment [3]

北京商报讯（记者 王寅浩 宋雨盈）2月27日，昊海生科发布2025年业绩快报，2025年度公司实现营业总 收入24.73亿元，同比减少8.33%；实现归属于母公司所有者的净利润2.51亿元，同比减少40.3%；实现 归属于母公司所有者的扣除非经常性损益的净利润1.6亿元，同比减少57.67%。 ...

Core Viewpoint - The company, Haohai Biological Technology, reported a significant decline in its financial performance for the fiscal year 2025, with total revenue and net profit both decreasing substantially compared to the previous year [1][2]. Financial Performance - Total revenue for 2025 was approximately 2.473 billion yuan, representing a year-on-year decrease of 8.33% [1]. - Net profit attributable to the parent company was around 251 million yuan, down 40.3% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was about 160 million yuan, reflecting a 57.67% decrease compared to the previous year [1]. - Basic earnings per share were reported at 1.08 yuan [1]. Market Conditions - The company faced significant operational pressure in its subsidiary, Shenzhen New Industry, due to the second phase of the national volume-based procurement for artificial lenses, leading to increased competition and a decline in market demand [2]. - The total number of cataract surgeries in China in 2025 is expected to decrease compared to 2024, contributing to a downturn in overall market demand [2]. - The sales price and volume of Lenstec brand products continued to decline throughout 2025, impacting the expected operating profit of Shenzhen New Industry [2]. Impairment Provisions - The company has made a prudent decision to recognize an impairment provision of approximately 140 million yuan for the goodwill associated with Shenzhen New Industry, in light of the anticipated price reductions in the upcoming round of national volume-based procurement [2]. - The impairment amount is subject to final assessment and audit by qualified evaluation and auditing institutions [2]. - Additionally, the company's U.S. subsidiary, Aaren Scientific Inc., has also indicated signs of impairment for its intangible assets, leading to a preliminary impairment provision of about 24.98 million yuan [3].

格隆汇2月27日丨昊海生物科技(06826.HK)发布2025年度业绩快报。报告期内，集团实现营业收入人民 币24.73亿元，同比减少8.33%；实现归属于母公司所有者的净利润为人民币2.51亿元，同比减少 40.30%；实现归属于母公司所有者的扣除非经常性损益的净利润为人民币1.6亿元，同比减少57.67%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2025年度業績快報公告 上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 《證券及期貨條例》（香港法例第571章）第XIVA部及《香港聯合交易所有限公司證 券上市規則》第13.09及13.10B條的要求發佈本公告，旨在向本公司股東及公眾人 士提供本公司的財務資料。本公告亦同時在上海證券交易所網站發佈。 本公告所載本集團按照中國企業會計準則編製的截至2025年12月31日止年度（「報 告期」）主要財務數據為初步核算未經核數師審計的數據。本集團報告期的具體財 務數據及經營業績將以本公司截至2025年12月31日止年度經審核之業績公告及本 公司2025年度報告所披露者為準。提請本公司潛在 ...

证券代码：688366 证券简称：昊海生科 公告编号：2026-002 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以上海昊海生物科技股份有限公司（以下简称"公司"）2025年年 度报告中披露的数据为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 247,301.23 | 269,765.79 | -8.33 | | 营业利润 | 22,049.65 | 49,476.14 | -55.43 | | 利润总额 | 23,953.17 | 46,614.55 | -48.61 | | 归属于母公司所有者的净利 润 | 25,100.61 | 42,044.69 | -40.30 | | 归属于母公司所有者的扣除 非经常性损益的净利润 | 16,048.17 | 37, ...